145 related articles for article (PubMed ID: 38349565)
1. ASO Author Reflections: Adjuvant Therapy for Resectable Pancreatic Cancer in the Real World-Not as Common as One Might Think.
Paiella S; Malleo G; Casciani F; Salvia R
Ann Surg Oncol; 2024 May; 31(5):2959-2960. PubMed ID: 38349565
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Pancreatic Cancer Having Tumor Contact with an Aberrant Right Hepatic Artery Should be Regarded as Technically Resectable but Oncologically Borderline-Resectable.
Miura Y; Ohgi K; Sugiura T; Okamura Y; Ashida R; Yamada M; Otsuka S; Yasunaga Y; Nakagawa M; Uesaka K
Ann Surg Oncol; 2022 Aug; 29(8):4989-4990. PubMed ID: 35445900
[No Abstract] [Full Text] [Related]
3. ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer-Resection Cuts the Deal.
Eshmuminov D; Aminjonov B; Palm RF; Lehmann K
Ann Surg Oncol; 2023 Jul; 30(7):4429-4430. PubMed ID: 37074518
[No Abstract] [Full Text] [Related]
4. ASO Author Reflections: Novel Evidence on Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer with Arterial Involvement.
Ikenaga N; Miyasaka Y; Ohtsuka T; Nakamura M
Ann Surg Oncol; 2023 Jan; 30(1):203-204. PubMed ID: 36131116
[No Abstract] [Full Text] [Related]
5. ASO Author Reflections: Size Matters in Distal Pancreatic Cancer: Predictor for Failure of Upfront Resection for Radiologically Resectable Disease.
Ito H; Watanabe G; Inoue Y; Takahashi Y
Ann Surg Oncol; 2022 Dec; 29(Suppl 3):568-569. PubMed ID: 34432193
[No Abstract] [Full Text] [Related]
6. ASO Author Reflections: Reconsidering the Treatment Strategy for Resectable Pancreatic Cancer Using a Biomarker-Based Scoring System for Prediction of Early Recurrence.
Ishido K; Kimura N; Wakiya T; Nagase H; Hara Y; Kanda T; Fujita H; Hakamada K
Ann Surg Oncol; 2022 Feb; 29(2):1294-1295. PubMed ID: 34811620
[No Abstract] [Full Text] [Related]
7. ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy Changes Body Composition Influencing Long-term Outcomes.
Takaichi S; Tomimaru Y; Kobayashi S; Toya K; Sasaki K; Iwagami Y; Yamada D; Noda T; Takahashi H; Asaoka T; Tanemura M; Doki Y; Eguchi H
Ann Surg Oncol; 2023 Apr; 30(4):2469-2470. PubMed ID: 36567385
[No Abstract] [Full Text] [Related]
8. ASO Author Reflections: Timing of Systemic Therapy and Postoperative Morbidity in Resectable Pancreatic Ductal Adenocarcinoma and Distal Cholangiocarcinoma.
Macfie R; Cohen N
Ann Surg Oncol; 2023 Aug; 30(8):5035. PubMed ID: 37179272
[No Abstract] [Full Text] [Related]
9. ASO Author Reflections: The Safety and Efficacy of Robot-Assisted and Laparoscopic Distal Pancreatectomy in Patients with Resectable Left-Sided Pancreatic Cancer.
van Ramshorst TME; Chen JW; Abu Hilal M; Besselink MG
Ann Surg Oncol; 2023 May; 30(5):3033-3034. PubMed ID: 36745254
[No Abstract] [Full Text] [Related]
10. ASO Author Reflections: Multimodality Therapy for Patients with Pancreatic Cancer: Neoadjuvant Therapy for All?
da Costa WL; Massarweh NN
Ann Surg Oncol; 2021 Jun; 28(6):3196-3197. PubMed ID: 33221979
[No Abstract] [Full Text] [Related]
11. ASO Practice Guidelines Series: Management of Resectable, Borderline Resectable, and Locally Advanced Pancreas Cancer.
Turner KM; Wilson GC; Patel SH; Ahmad SA
Ann Surg Oncol; 2024 Mar; 31(3):1884-1897. PubMed ID: 37980709
[TBL] [Abstract][Full Text] [Related]
12. ASO Author Reflections: Neoadjuvant Treatment of Resectable and Borderline-Resectable Pancreatic Head Adenocarcinoma: Is FOLFIRINOX Better than Gem/Nab-Paclitaxel?
Dhir M; Zureikat AH
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):808-809. PubMed ID: 30298324
[No Abstract] [Full Text] [Related]
13. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Xie H; Liu J; Yin J; Ogden JR; Mahipal A; McWilliams RR; Truty MJ; Bekaii-Saab TS; Petersen GM; Jatoi A; Hubbard JM; Ma WW
Oncologist; 2020 Nov; 25(11):e1681-e1690. PubMed ID: 32663355
[TBL] [Abstract][Full Text] [Related]
14. ASO Author Reflections: Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer.
Andrianello S; Marchegiani G; Salvia R
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):810-811. PubMed ID: 30374921
[No Abstract] [Full Text] [Related]
15. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma.
Sakaguchi T; Satoi S; Yamamoto T; Yamaki S; Sekimoto M
Surg Today; 2020 Apr; 50(4):335-343. PubMed ID: 31993761
[TBL] [Abstract][Full Text] [Related]
16. The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer.
Kimple RJ; Russo S; Monjazeb A; Blackstock AW
Expert Rev Anticancer Ther; 2012 Apr; 12(4):469-80. PubMed ID: 22500684
[TBL] [Abstract][Full Text] [Related]
17. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.
Abrams RA; Lowy AM; O'Reilly EM; Wolff RA; Picozzi VJ; Pisters PW
Ann Surg Oncol; 2009 Jul; 16(7):1751-6. PubMed ID: 19390900
[No Abstract] [Full Text] [Related]
18. ASO Author Reflections: Postoperative Carbohydrate Antigen 19-9 Levels Become a Reliable Biomarker for Establishing Intensity-Stratified Adjuvant Treatments in Pancreatic Ductal Adenocarcinoma.
Ariake K; Okada T; Tsuchiya H; Kuboki D; Maemura K; Ichikawa H; Tachibana T; Akazawa N; Abe T; Kakita T; Oikawa M; Tsuchiya T
Ann Surg Oncol; 2024 Jan; 31(1):548-549. PubMed ID: 37907696
[No Abstract] [Full Text] [Related]
19. ASO Author Reflections: From Concept to Real Clinical Practice of Laparoscopic Distal Pancreatectomy for Left-Sided Pancreatic Cancer.
Kang CM
Ann Surg Oncol; 2020 Dec; 27(13):5237-5238. PubMed ID: 32462529
[No Abstract] [Full Text] [Related]
20. ASO Author Reflections: Irreversible Electroporation for Locally Advanced Pancreatic Cancer.
Tsilimigras DI; Moris D; Pawlik TM
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):610-611. PubMed ID: 31087182
[No Abstract] [Full Text] [Related]
[Next] [New Search]
